Luciano Zardi

Dr. Luciano Zardi


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2003
Verified
Journal Article
Closed access
MSMonica Santimaria
Monica Santimaria
GMGiovanni Moscatelli
Giovanni Moscatelli
GVGiuseppe L Viale
Giuseppe L Viale
LGLeonardo Giovannoni
Leonardo Giovannoni
GNGiovanni Neri
Giovanni Neri
PRPietro Riva
Pietro Riva

15 June 2003
Verified
Journal Article
Closed access
CHCornelia Halin
Cornelia Halin
VGVerena Gafner
Verena Gafner
MVMaria Elena Villani
Maria Elena Villani
LBLaura Borsi
Laura Borsi
ABAlexander Berndt
Alexander Berndt
DNDario Neri
Dario Neri

11 June 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EBEnrica Balza
Enrica Balza
FSFrancesca Sassi
Francesca Sassi
EVElisa Ventura
Elisa Ventura
APArianna Parodi
Arianna Parodi
SFSara Fossati
Sara Fossati
LBLaura Borsi
Laura Borsi
The angiogenesis‐associated extra‐domain B (EDB) of fibronectin (FN) is a complete type III repeat of 91 amino acids. Its expression is modulated by the alternative splicing pattern of the FN pre‐mRNA. FN containing the EDB (B‐FN) is undetectable in tissues of healthy adults, with rare exceptions such as the female reproductive system where tissue remodeling and angiogenesis are recurrent physiological processes. On the contrary, B‐FN is expressed at high levels in neoplastic tissues and during angiogenesis; consequently, it is considered an excellent marker of angiogenesis. Here, we report on a novel FN cryptic sequence, localized on the FN type III repeat 8 (immediately downstream of the EDB) that is unmasked by the insertion of the EDB. This sequence is specifically recognized by the high‐affinity monoclonal antibody, C6, that selectively recognizes B‐FN by means of ELISA, immunohistochemical and Western blot assays. The variable regions of C6 were cloned and a divalent covalently linked mini‐antibody was generated. Biodistribution studies using the radioiodinated C6 mini‐antibody on tumor‐bearing mice demonstrated an efficient tumor targeting. This antibody represents a new tool for the study of the potential biological functions of hindered sequences that the inclusion of the EDB renders accessible, and likewise makes its epitope an additional angiogenesis target. © 2009 UICC.

10 February 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EVElisa Ventura
Elisa Ventura
FSFrancesca Sassi
Francesca Sassi
APArianna Parodi
Arianna Parodi
EBEnrica Balza
Enrica Balza
LBLaura Borsi
Laura Borsi
LZLuciano Zardi
Luciano Zardi
Fibronectin (FN) is a multi-domain molecule involved in many cellular processes, including tissue repair, embryogenesis, blood clotting, and cell migration/adhesion. The biological activities of FN are mediated by exposed loops located mainly at the interdomain interfaces that interact with various molecules such as, but not only, integrins. Different FN isoforms arise from the alternative splicing of the pre-mRNA. In malignancies, the splicing pattern of FN pre-mRNA is altered; in particular, the FN isoform containing the extra-domain B (ED-B), a complete FN type III repeat constituted by 91 residues, is undetectable in normal adult tissues, but exhibits a much greater expression in fetal and tumor tissues, and is accumulated around neovasculature during angiogenic processes, thus making ED-B one of the best markers and targets of angiogenesis. The functions of ED-B are still unclear; however, it has been postulated that the insertion of an extra-domain such as ED-B modifies the domain-domain interface and may unmask loops that are otherwise cryptic, thus giving FN new potential activities. We used the mAb C6, which reacts with ED-B containing FN, but not with ED-B-free FN and various recombinant FN fragments containing mutations, to precisely localize the epitopes recognized by the mAb C6. We formally demonstrated that the inclusion of the alternatively spliced angiogenesis-associated ED-B leads to the unmasking of the FNIII 8 B-C loop that is cryptic in FN molecules lacking ED-B. Thus, the mAb C6, in addition to providing a new reagent for angiogenesis targeting, represents a new tool for the study of the potential biological functions of the B-C loop of the repeat FNIII 8 that is unmasked during angiogenic processes.

10 November 2011 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
EVElisa Ventura
Elisa Ventura
EBEnrica Balza
Enrica Balza
LBLaura Borsi
Laura Borsi
GTGiorgia Tutolo
Giorgia Tutolo
BCBarbara Carnemolla
Barbara Carnemolla
LZLuciano Zardi
Luciano Zardi
Background: Ligand-targeted approaches have proven successful in improving the therapeutic index of a number of drugs. We hypothesized that the specific targeting of TNF-alpha antagonists to inflamed tissues could increase drug efficacy and reduce side effects. Results: Using uteroglobin (UG), a potent anti-inflammatory protein, as a scaffold, we prepared a bispecific tetravalent molecule consisting of the extracellular ligand-binding portion of the human TNF-alpha receptor P75 (TNFRII) and the scFv L19. L19 binds to the ED-B containing fibronectin isoform (B-FN), which is expressed only during angiogenesis processes and during tissue remodeling. B-FN has also been demonstrated in the pannus in rheumatoid arthritis. L19-UG-TNFRII is a stable, soluble homodimeric protein that maintains the activities of both moieties: the immuno-reactivity of L19 and the capability of TNFRII to inhibit TNF-alpha. In vivo bio-distribution studies demonstrated that the molecule selectively accumulated on B-FN containing tissues, showing a very fast clearance from the blood but a very long residence time on B-FN containing tissues. Despite the very fast clearance from the blood, this fusion protein was able to significantly improve the severe symptomatology of arthritis in collagen antibody-induced arthritis (CAIA) mouse model. Conclusions: The recombinant protein described here, able to selectively deliver the TNF-alpha antagonist TNFRII to inflamed tissues, could yield important contributions for the therapy of degenerative inflammatory diseases.

1 September 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
EVElisa Ventura
Elisa Ventura
FSFrancesca Sassi
Francesca Sassi
SFSara Fossati
Sara Fossati
APArianna Parodi
Arianna Parodi
WBWilliam Blalock
William Blalock
LZLuciano Zardi
Luciano Zardi
We report a novel strategy to engineer and express stable and soluble human recombinant polyvalent/polyspecific fusion proteins. The procedure is based on the use of a central skeleton of uteroglobin, a small and very soluble covalently linked homodimeric protein that is very resistant to proteolytic enzymes and to pH variations. Using a human recombinant antibody (scFv) specific for the angiogenesis marker domain B of fibronectin, interleukin 2, and an scFv able to neutralize tumor necrosis factor-α, we expressed various biologically active uteroglobin fusion proteins. The results demonstrate the possibility to generate monospecific divalent and tetravalent antibodies, immunocytokines, and dual specificity tetravalent antibodies. Furthermore, compared with similar fusion proteins in which uteroglobin was not used, the use of uteroglobin improved properties of solubility and stability. Indeed, in the reported cases it was possible to vacuum dry and reconstitute the proteins without any aggregation or loss in protein and biological activity.